drugset / Trial / NCT00957385

Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients

NCT00957385

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if Revlimid will help maintain patients with acute myeloid leukemia in remission.

Timeline

Start
2008-06
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lenalidomide Other / unclassified 10 mg Oral